

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Nir Dotan, *et al.* CONFIRMATION NO.: 7497
U.S. PATENT No.: 7,592,150 ISSUE DATE: September 22, 2009
SERIAL NUMBER : 10/728,227 EXAMINER : J. L. Grun
FILING DATE : December 3, 2003 ART UNIT : 1641
FOR : METHOD FOR DIAGNOSING DISEASES BASED ON LEVELS OF ANTI-GLYCAN
ANTIBODIES

Certificate of Correction Branch

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR § 1.322

The patentee of the above-identified patent, through its attorney, hereby requests issuance of a Certificate of Correction. A certificate is required to correct errors, as follows:

The claims:

Column 27, Line 12, Claim 10, "can antibody in said sample is an IgC isotype antibody." should read -- can antibody in said sample is an IgG isotype antibody. --

Column 27, Lines 25-26, Claim 12, "as having Crohn's disease if said ALCA and said polysaccharide (β 1-3) Glucan antibody levels are elevated in said," should read -- as having Crohn's disease if said ALCA and said polysaccharide β -D (1-3) Glucan antibody levels are elevated in said --

Column 27, Line 62, Claim 18, "(α 1-3) [Man (α 1-6)] Man (α) antibody, anti-Man (α 1-2)," should read -- (α 1-3) Man (α) antibody, anti-Man (α 1-3)[Man (α 1-6)] Man (α) antibody, anti-Man (α 1-2) --

Column 29, Line 4, Claim 35, "detected with an enzyme-linked inununoabsorbent assay," should read -- detected with an enzyme-linked immunoabsorbent assay --

Column 29, Line 11, Claim 37, "GleNAc (β) antibody (ACCA) or an anti-polysaceharide β -D," should read -- GleNAc (β) antibody (ACCA) or an anti-polysaccharide β -D --

Column 29, Line 14, Claim 37, "anti-polysaceharide β -D (1-3) Glucan antibody levels are," should be -- anti-polysaccharide β -D (1-3) Glucan antibody levels are --

Applicant: Nir Dotan, et al.
Patent Number: 7,592,150

Column 29, Lines 36-37, Claim 42, "comprises detecting a level of an anti-GlcNAc (β 1-4) GlcNAc (β) antibody (ACCA) and an anti-polysaccharide," should be -- comprises detecting a level of an anti-GlcNAc (β 1-4) GlcNAc (β) antibody (ACCA) and an anti-polysaccharide --

Column 30, Line 29, Claim 50, "IgG ALCA, IgC ASCA, or IgA ASCA antibodies are" should read -- IgG ALCA, IgG ASCA, or IgA ASCA antibodies are --

Column 30, Line 57, Claim 53, "GlcNAc (β) glycan, said Glc(β 1-3) Glc (β), said mannan, and" should read -- GlcNAc (β), said Glc(β 1-3) Glc (β), said mannan, and --

The corrections are not believed to involve such change as would constitute new matter or require examination.

It is respectfully requested that a Certificate of Correction be issued pursuant to 35 U.S.C. 254 to correct the errors in the claims. Enclosed herewith is a copy of a proposed Certificate of Correction indicating the errors and corrections thereof.

No fees are believed due in connection with this submission, however, the Commissioner is hereby authorized to charge any fees due, or credit any overpayment of same, to Deposit Account No. 50-0311; Reference No. 25681-502P.

Respectfully submitted,



Ingrid A. Beattie Reg. No. 42,306
Attorneys for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer Number 30623

Dated: October 14, 2009

ACTIVE 4732318v.1